Printed from Voxsanity (voxsanity.com.au) — NCT06085378 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.
Back to Type 2 Diabetes
Type 2 Diabetes Trial, Not Yet Recruiting
NCT06085378
voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice
Who may and may not be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who may be able to join
- Adults aged 18 to 80 years old.
- People who have been diagnosed with an acute ischemic stroke (a stroke caused by a blocked blood vessel in the brain) classified as either a complete or partial front-of-brain circulation stroke, based on a recognised stroke classification system.
- People who have been diagnosed with type 2 diabetes, confirmed by medical records, according to Chinese diabetes guidelines (2020 edition).
- People who arrived at hospital within 48 hours of their stroke starting — if the exact start time is unknown, the time when the person last appeared well is used as the starting point.
- People experiencing their first-ever ischemic stroke, or people who have had a previous ischemic stroke but had little to no lasting disability before this stroke occurred.
- People with a stroke severity score (NIHSS) between 6 and 20.
- People who have given signed written consent to participate, either themselves or through their legal representative.
Who may not be able to join
Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.
- People whose brain scans show any type of bleeding in or around the brain, such as a brain bleed, blood clot between the brain and skull, or bleeding in the spaces around the brain.
- People who have had, or are planned to have, a procedure to physically open or treat a blocked blood vessel in the brain (intravascular interventional therapy) after the stroke.
- People who have received, or are planned to receive, clot-dissolving medication given through a drip (intravenous thrombolysis) after the stroke.
- People with a severe reduction in consciousness, as measured by a specific part of the stroke severity scoring scale (NIHSS consciousness score of 2 or more).
- People who have a bone fracture, limb pain when walking, or other conditions that would affect the ability to measure physical function scores at the time of admission.
- People who have already been given certain specific brain-protective or blood-flow medications (Edaravone injection, Edaravone and Dexborneol solution, Butylphthalide injection, or Butylphthalide soft capsules) after this stroke occurred.
- People who have already received certain traditional Chinese medicine injections aimed at improving blood flow to the brain after this stroke occurred (confirm specific medicines with trial site).
- People whose blood pressure is lower than 90/60 mmHg at the time of admission.
- People with a history of severe food or drug allergies, or who have previously had an allergic reaction or intolerance to the study drug (Eurecline injection).
- People who have taken a type of blood-pressure medication called an ACE inhibitor (ACEI) and have not yet waited the required clearance time before starting the study drug (confirm timeframe with trial site).
- People who are pregnant, breastfeeding, or planning to become pregnant within 90 days.
- People with kidney failure or severely reduced kidney function at the time of screening (creatinine clearance below 30 ml/min).
- People with significant liver problems, including liver enzyme levels more than 2.5 times the upper normal limit, or known serious liver conditions such as active hepatitis or cirrhosis.
- People who have experienced heart failure (classified as severe — NYHA class III or IV), unstable chest pain, a heart attack, serious irregular heart rhythms, or significant heart conduction problems in the 6 months before joining the trial.
- People who have been drinking heavily in the 3 months before screening, defined as 5 or more standard drinks per day (where one standard drink equals approximately 120 ml of wine, 360 ml of beer, or 45 ml of spirits).
- People who have misused or been dependent on drugs or narcotics in the past year.
- People with a cancer diagnosis or serious illness where survival is expected to be less than 90 days.
- People with serious mental health conditions or dementia that would prevent them from giving informed consent or completing follow-up visits.
- People who have taken part in any other clinical trial involving a drug or medical device in the 3 months before screening.
- People the trial investigator considers unsuitable for the study for any other reason.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
Contact this trial
Principal Investigator: Jinsheng Zeng, First Affiliated Hospital, Sun Yat-Sen University
Phone: +8613322800657
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Status
Not Yet Recruiting
Phase
Not Applicable
Sponsor
First Affiliated Hospital, Sun Yat-Sen University
Registry
ClinicalTrials.gov
Start date
1 January 2024
Est. completion
31 December 2026
Where this trial is recruiting
🇨🇳 China
Primary endpoints
The proportion of patients with modified rankin scale (mRS) 0-2 scores at 90±7 days
Can't join this trial?
Data last synced from ClinicalTrials.gov: 31 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.
Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.